RxDoctor Payments Data

Kylee Stanley, MD

Internal Medicine · Fremont, NENPI 1619236379

Payments from drug & device makers

$1,959in general payments, 2019–2025

Across 122 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$382
  • Pfizer$190
  • Amgen$168
  • Boehringer Ingelheim$122
  • Lilly USA, LLC$117
  • AstraZeneca$108
  • plus $871 from 30 others

What the payments were for

  • Food & beverage$1,959100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,959 in reported general payments places this provider in the 85th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$354,565
Medicare patients
394
Services billed
9,742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban522$366,638
MounjaroTirzepatide88$92,906
OzempicSemaglutide72$74,118
FarxigaDapagliflozin Propanediol78$49,965
RybelsusSemaglutide41$47,398
JardianceEmpagliflozin43$36,914
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$28,941
EntrestoSacubitril/Valsartan53$18,234
JanuviaSitagliptin Phosphate32$16,432
GemtesaVibegron30$11,984
MyrbetriqMirabegron30$11,807
Spiriva HandihalerTiotropium Bromide19$10,049
Atorvastatin Calcium940$9,530
Pantoprazole Sodium601$7,412
Lantus SolostarInsulin Glargine,hum.Rec.Anlog65$6,518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$190$366,638522 claims
Novo NordiskOzempic, Rybelsus, Novolog$382$125,340125 claims
Lilly USA, LLCMounjaro$117$92,90688 claims
AstraZenecaFarxiga$108$49,96578 claims
Boehringer IngelheimJardiance$122$36,91443 claims
GSKTrelegy Ellipta, Breo Ellipta$50$34,47648 claims
NovartisEntresto$21$18,23453 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Fremont

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →